Table 1.
Patient demographics and graft characteristics.
| Characteristics | N = 56 |
|---|---|
| Median Age (range) | 29.5 years (2–64) |
| N (%) Male | 30 (54%) |
| Median Weight (range) | 68 kg (13–118) |
| N (%) Recipient CMV Seropositive | 28 (50%) |
| N (%) Diagnosis | |
| AML* | 24 (43%) |
| ALL | 15 (27%) |
| MDS or CML | 4 (7%) |
| Lymphoma | 13 (23%) |
| Conditioning | |
| TBI 1320–1375 with Cy/Flu or Thio/Flu | 32 (57%) |
| Cy/Flu/Thio/TBI 400 | 15 (27%) |
| Clo/Mel/Thio** | 3 (5%) |
| Mel/Flu** | 6 (11%) |
| Donor-recipient HLA-Match (N = 112 units) | |
| 6/6 | 3 |
| 5/6 | 59 |
| 4/6 | 50 |
| Median Infused TNC × 107/kg (range) | |
| Larger Unit | 2.7 (1.5–7.3) |
| Smaller Unit | 1.9 (0.9–5.3) |
| Median Infused CD34+ × 105/kg (range) | |
| Larger Unit | 1.1 (0.3–6.4) |
| Smaller Unit | 0.7 (0.1–1.5) |
Abbreviations: N, number; Kg, kilogram; CMV, cytomegalovirus; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; CML, chronic myelogenous leukemia; TBI, total body irradiation; Cy, cyclophosphamide; Flu, fludarabine; Thio, thiotepa; Clo, clofarabine; Mel, melphalan; HLA, human leukocyte antigen.
*
Includes 2 patients with biphenotypic acute leukemia.
**
The melphalan doses in these regimens were 140 mg/m2.